Explore evidence-based treatments for complex mental health conditions. Discover detailed protocols, essential safety information, and what to confidently expect on your path to wellness.
FDA-cleared for Treatment-Resistant Depression (TRD) OCD, and smoking cessation.
FDA-approved for Treatment-Resistant Depression with or without an oral antidepressant, and Depression with suicidal intent.
Exploring off-label use for treatment-resistant conditions.
Duration: 120 minutes.
Environment: Experience treatment in a private suite, semi-private suite, or open space with a calming ambiance, fostering peace and focus.
Monitoring: Continuous cardiac and pulse oximetry monitoring ensures your safety throughout.
| TMS | SPRAVATO® | KETAMINE | |
|---|---|---|---|
| ADMINISTRATION | Non-invasive | Nasal Spray | IV Infusion |
| SESSION FREQUENCY | Weekly (6-8 wks) or Daily (5-6 days) | 1-2x per week | 1-2x per week |
| TIME COMMITMENT | 20-30 minutes | 2.5 hours | 2 hours |
| FDA STATUS |
Cleared: TRD, OCD, Smoking Cessation Off-label: bipolar disorder, PTSD, schizophrenia, Alzheimer's, autism, chronic pain, multiple sclerosis, Parkinson's, anxiety, ADHD, and post-stroke rehabilitation. |
Approved: TRD | Off-label |
| BEST FOR | Medication-resistant cases | Acute symptom relief | Complex comorbid conditions |
"*" indicates required fields